NR3C1 and Duchenne muscular dystrophy: Although other anti-inflammatories have failed clinical trials (Finkel et al., 2021), our results here, along with the consistent efficacy of prednisone, deflazacort and vamorolone, indicate that the specific mechanism by which the GR ligands inhibit inflammation in myofibers may be an essential driver of efficacy in DMD.